Evidence map›Paper›PMID 29536777›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2018

Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.

Minhang Xin, Weiming Duan, Yifan Feng, Yuan-Yuan Hei, Hao Zhang, Ying Shen, Hong-Yi Zhao, Shuai Mao, San-Qi Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Minhang Xina Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Weiming Duana Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Yifan Fenga Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Yuan-Yuan Heia Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Hao Zhanga Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Ying Shena Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Hong-Yi Zhaoa Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Shuai Maoa Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
San-Qi Zhanga Department of Medicinal Chemistry, School of Pharmacy , Health Science Center, Xi'an Jiaotong University , Xi'an , P.R. China.
Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphoinositide 3-kinase Delta (PI3Kδ) plays a key role in B-cell signal transduction and inhibition of PI3Kδ was confirmed to have clinical benefit in certain types of activation of B-cell malignancies. Herein, we reported a novel series of 4-pyrrolidineoxy or 4-piperidineamino substituted quinazolines, showing potent PI3Kδ inhibitory activities. Among these compounds, 12d, 14b and 14c demonstrated higher potency against PI3Kδ with the half maximal inhibitory concentration (IC

Indexed as

Class I Phosphatidylinositol 3-KinasesDose-Response Relationship, DrugHumansMolecular StructurePiperidinesProtein Kinase InhibitorsPyrrolidinesQuinazolinesStructure-Activity RelationshipClass I Phosphatidylinositol 3-KinasesPIK3CD protein, humanpiperidinePiperidinesProtein Kinase InhibitorsPyrrolidinesQuinazolines4-piperidineamino4-pyrrolidineoxyanti-proliferationPI3Kδ inhibitorsselectivity

Identifiers

PMID29536777
PMCPMC6009876
OpenAlexW2790118692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.